SYGNIS to Present its Innovative TruePrime™ Technology to Next Generation Sequencing Experts at VIB’s internationally renowned Tools and Technologies Meeting
Madrid, Spain and Heidelberg, Germany, January 14th – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced it will present its revolutionary novel multi displacement amplification (MDA) technology TruePrime™ to established experts in the field of next generation sequencing (NGS) at VIB’s Meeting “Revolutionizing Next-Generation Sequencing: Tools and Technologies” on January 15th, during the afternoon Parallel session 2 at 4:35 PM in the Kinepolis in Leuven, Belgium. This highly recognized conference is one of the key platforms for scientific players in the field of next generation sequencing worldwide.
A major challenge for next generation sequencing applications is the limited amount of DNA available, especially when working with single or a few cells gained from, for example, biopsies in cancer research. Based on the recently discovered primase TthPrimPol, SYGNIS’ TruePrime™ technology stands for a revolutionary change in the way the amount of DNA or RNA in a sample can be amplified. While the current gold standard in MDA needs short pieces of DNA (“oligonucleotides”) to start off whole genome amplification, TruePrime™ does not need any synthetic random primers.
Professor Dr. Armin Schneider, Senior Vice President Research at SYGNIS commented: “We are very proud and excited about the opportunity to introduce our next generation multiple displacement DNA amplification technology to such a selected group of experts. I am very much looking forward to discussing the outstanding advantages and the superior results that researchers can achieve when using our TruePrime™ MDA technology.”
More information about the VIB Meeting “Revolutionizing Next Generation Sequencing: Tools and Technologies” can be found here.
The Company is currently developing a complete range of DNA and RNA amplification kits based on its proprietary TruePrime™ MDA technology. The first product for whole genome amplification from single cells is expected to be launched this month.
Press Release as PDF
For further information please contact:
Pilar de la Huerta, CEO/CFO